Literature DB >> 19067649

Elucidating isoniazid resistance using molecular modeling.

Habibah A Wahab1, Yee-Siew Choong, Pazilah Ibrahim, Amirin Sadikun, Thomas Scior.   

Abstract

The continuing rise in tuberculosis incidence and the problem of drug resistance strains have prompted the research on new drug candidates and the mechanism of drug resistance. Molecular docking and molecular dynamics simulation (MD) were performed to study the binding of isoniazid onto the active site of Mycobacterium tuberculosis enoyl-acyl carrier protein reductase (InhA) in an attempt to address the mycobacterial resistance against isoniazid. Results show that isonicotinic acyl-NADH (INADH) has an extremely high binding affinity toward the wild type InhA by forming stronger interactions compared to the parent drug (isoniazid) (INH). Due to the increase of hydrophobicity and reduction in the side chain's volume of A94 of mutant type InhA, both INADH and the mutated protein become more mobile. Due to this reason, the molecular interactions of INADH with mutant type are weaker than that observed with the wild type. However, the reduced interaction caused by the fluctuation of INADH and the mutant protein only inflected minor resistance in the mutant strain as inferred from free energy calculation. MD results also showed there exists a water-mediated hydrogen bond between INADH and InhA. However, the bridged water molecule is only present in the INADH-wild type complex, reflecting the putative role of the water molecule in the binding of INADH to the wild type protein. The results support the assumption that the conversion of prodrug isoniazid into its active form INADH is mediated by KatG as a necessary step prior to target binding on InhA. Our findings also contribute to a better understanding of INH resistance in mutant type.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19067649     DOI: 10.1021/ci8001342

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  5 in total

Review 1.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.

Authors:  Sean Ekins; Joel S Freundlich; Inhee Choi; Malabika Sarker; Carolyn Talcott
Journal:  Trends Microbiol       Date:  2010-12-02       Impact factor: 17.079

2.  Elucidating drug-enzyme interactions and their structural basis for improving the affinity and potency of isoniazid and its derivatives based on computer modeling approaches.

Authors:  Auradee Punkvang; Patchreenart Saparpakorn; Supa Hannongbua; Peter Wolschann; Pornpan Pungpo
Journal:  Molecules       Date:  2010-04-16       Impact factor: 4.411

Review 3.  In Silico Strategies in Tuberculosis Drug Discovery.

Authors:  Stephani Joy Y Macalino; Junie B Billones; Voltaire G Organo; Maria Constancia O Carrillo
Journal:  Molecules       Date:  2020-02-04       Impact factor: 4.411

4.  The binding characteristics of isoniazid with copper-zinc superoxide dismutase and its effect on enzymatic activity.

Authors:  Nana Du; Liangquan Sheng; Zhaodi Liu; Xiaojuan Hu; Huajie Xu; Shuisheng Chen
Journal:  Chem Cent J       Date:  2013-06-06       Impact factor: 4.215

5.  Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance.

Authors:  Jody Phelan; Francesc Coll; Ruth McNerney; David B Ascher; Douglas E V Pires; Nick Furnham; Nele Coeck; Grant A Hill-Cawthorne; Mridul B Nair; Kim Mallard; Andrew Ramsay; Susana Campino; Martin L Hibberd; Arnab Pain; Leen Rigouts; Taane G Clark
Journal:  BMC Med       Date:  2016-03-23       Impact factor: 8.775

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.